Product Description: MPD2 is a PROTAC (Proteolysis Targeting Chimera) reducer that targets SARS-CoV-2's main protease (MPro). MPD2 reduces MPro protein levels through time-dependent, CRBN (Cereblon) mediated and proteasoma-driven mechanisms. MPD2 has the potential to be an antiviral small molecule compound against a variety of SARS-CoV-2 strains, including drug-resistant strains[1].
Formula: C51H68N6O13
References: [1]Yugendar R. Alugubelli, et al. Discovery of First-in-Class PROTAC Degraders of SARS-CoV‑2 MainProtease.Journal of Medicinal Chemistry. 2024 Apr 25,67(8):6495-6507.
Molecular Weight: 973.12
Research Area: Infection
Target: SARS-CoV